



Contents lists available at ScienceDirect

Journal of King Saud University – Science

journal homepage: www.sciencedirect.com

Original article

Zoonotic risk and public health hazards of companion animals in the transmission of *Helicobacter* species

Ihab M. Moussa^{a,b,*}, Jakeen Eljakee^b, Mariam Beder^c, Kareem Abdelaziz^d, Ayman S. Mubarak^a, Turki M. Dawoud^a, Hassan A. Hemeg^e, Roua A. Alsubki^f, Saleh A. Kabli^g, Sherif Marouf^b^a Department of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia^b Microbiology Department, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt^c Veterinary Administration in General Organization for Veterinary Services, Egypt^d Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt^e Department of Medical Technology/Microbiology, College of Applied Medical Science, Taibah University, Madinah, Saudi Arabia^f Department of Clinical Laboratory Science, Chair of Medical and Molecular Genetics Research, College of Applied Medical Science, King Saud University, Saudi Arabia^g Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia

ARTICLE INFO

Article history:

Received 9 March 2021

Revised 12 April 2021

Accepted 23 May 2021

Available online 31 May 2021

Keywords:

Helicobacteriosis

*H. heilmannii**H. pylori**H. felis*

Gastric ulcer

ABSTRACT

Objective: Helicobacteriosis is worldwide infection caused by *Helicobacter* species that affects both humans and animals. The current work correlated the zoonotic and public health repertoire of *Helicobacter* species in companion animals (dogs and cats).

Methods: Samples were collected from apparently healthy dogs (70), cats (65), and 70 human patients who had been in contact with these animals in the Cairo and Giza governorates. The samples included serum, feces, and stool samples and biopsies of gastric fundus fragments (~5 mm). All samples were examined by culture, biochemical analysis, serology, and molecular identification.

Results: *Helicobacter* species were detected at a rate of 43.4% by PCR. *H. heilmannii* was more predominant, with a rate of 16%, whereas *H. pylori* was detected at 6%. *H. pylori* and *H. heilmannii* were isolated from both human and companion samples, whereas all samples were negative for *H. felis*.

Conclusion: Dogs and cats were reservoirs and played a major source in human helicobacters infection.

© 2021 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

The bacteria of dog were firstly found in the stomach mucosa and named as *Spirillum* (Rappin, 1958); subsequently, they were called *Spirochete*, then *Campylobacter*, and currently they are grouped in the *Helicobacter* genus (Lockard and Boler, 1970; Owen, 1998). The work was also documented by Bizzozero and Salomon in dogs, cats, and rats (Bizzozero, 1893; Salomon, 1896). The *Helicobacter* genus comprises approximately 21 species with gastric, intestinal, or hepatic distribution. The gastric *Helicobacter* species include *H. felis*, *H. bizzozeronii*, *H. salomonis*, "*H. heilmannii*,"

"*Flexispira rappini*," and *H. bilis* in dogs and cats and *H. pylori* in humans. The intestinal forms includes *H. fennelliae*, *H. cinaedi*, *H. canis*, and "*F. rappini*" in humans, dogs, and cats and *H. hepaticus*, *H. bilis*, *H. rodentium*, *H. muridarum*, and "*F. rappini*" in mice. *H. hepaticus* and *H. bilis* in mice, *H. canis* in dogs, and possibly *H. pylori* in humans are hepatic *Helicobacter* species (Shinozaki et al. 2002).

Many studies have concluded that gastric *Helicobacter* infections are present in both apparently healthy dogs and in those with clinically apparent gastric disease (Okubo et al. 2017). *Helicobacter* species vary according to geographic region and exhibit a prevalence of 86% to 100% in healthy dogs, 41% to 100% in healthy cats, up to 82% in diseased dogs, and up to 76% in affected cats. *H. pylori* infection is a worldwide, common, and lifelong infection (Crow et al., 2019). The *Helicobacter* species identified in gastritis and gastric ulcer pathogenic samples were incriminated as the inducing agents of gastric carcinoma in humans (Morgner et al. 2000). The degree of their colonization is not correlated the severity of gastritis in cats and dogs, although these bacteria were a predominant feature in the histopathology of the stomach (Ladeira et al. 2003).

* Corresponding author at: Department of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.

E-mail address: imoussa1@ksu.edu.sa (I.M. Moussa).

Peer review under responsibility of King Saud University.



Production and hosting by Elsevier

Pigs, dogs, and cats constitute reservoir hosts for gastric *Helicobacter* species with zoonotic potential. Moreover, *H. pylori* is a zoonotic pathogen that has been suggested to be transmitted from companion animals to humans (Ladeira et al. 1994), as similar morphological patterns of bacteria were detected in animals and humans with gastritis (Bulck et al. 2005). However, the exact transmission route remains unknown and many studies have reinforced the transmission hypothesis of oro-oral or oro-fecal routes, as *Helicobacter* spp. were isolated from the mouth and feces of infected dogs and cats (Hu et al. 2017).

Some *Helicobacter* species are non-culturable and different techniques depend on cultured organisms for accurate diagnosis (Cattoli et al. 1999). Serological tests for veterinary application to detect *Helicobacter* species are not yet clinically available. The detection of fecal *H. pylori* antigens is possible. PCR assay is a non-invasive, faster, simple, specific, and sensitive diagnostic test that will help recognize *Helicobacter* infection in humans and companion animals (Ford and Moayyedi, 2014).

The present investigation aimed at evaluating the incidence of *Helicobacter* spp. in companion animals and to assess their transmission role as a zoonotic risk.

2. Materials and methods

2.1. Ethics approval

2.1.1. Animal ethics

Animal samples were obtained according to the principles of the Declaration of Egypt and approved by the Veterinary Medicine Cairo University Institutional Animal Care and Use Committee (Ref; VETCU1022109045).

2.1.2. Human ethics

This study had full ethical approval from the Faculty of Medicine Ethics Committee based on the principles of the Declaration of Egypt.

2.2. Samples

Samples were collected from apparently healthy companion animals in the Cairo and Giza governorates. They included 70 dogs (30 serum samples, 30 feces samples, and 10 biopsies of gastric fundus fragments (~5 mm)), 65 cats (30 serum samples, 30 feces samples, and five biopsies of gastric fundus fragments (~3 mm)).

Seventy samples were collected from human patients who had been in contact with the companion animals under study and suffered from dyspepsia, chronic vomiting, and perforated peptic ulcer (30 serum samples, 30 stool samples, and 10 biopsies of gastric fundus fragments (~5 mm)).

All samples were collected over the period of March 2016 to March 2019 and were examined for the presence of *Helicobacter* species.

2.3. Microbiological identification of *Helicobacter* species

Five grams of feces, stool, and biopsy samples were bacteriologically homogenized separately with 15 ml of Brucella broth (Sigma, USA) containing 20% glycerol (Sigma-Aldrich, USA) and 0.5 g of cholestyramine (Sigma, USA). A loop-full was streaked onto Columbia blood agar plates (Oxoid) supplemented with *Helicobacter* selective supplement (SR0147E, Oxoid). All plates were incubated under microaerophilic conditions at 37 °C for 3–5 days. Purified colonies underwent Gram staining for microscopic examination, followed by biotyping based on catalase production, oxi-

dase production, urea hydrolysis, nitrate reduction, and salt tolerance (Forbes et al., 2007).

2.4. Serological analysis of *Helicobacter pylori*

Feces and stool samples were serologically analyzed for the presence of *H. pylori* antigens using Asan Easy Test *H. pylori* Ag (REF:24111, Korea), whereas serum samples were assessed for *H. pylori* antibodies using Asan Easy Test *H. pylori* Ab (REF:14131, Korea). The procedure and result reading were carried out according to the manufacturer's instructions.

2.5. Molecular identification

DNA was extracted from samples using a modified QIAamp mini kit (Qiagen, Switzerland). A 25- μ l PCR reaction containing 6 μ l of template, 1 μ l of each primer (20 pmol concentration), 12.5 μ l of PCR Master Mix (Emerland, Japan), and 4.5 μ l of deionized water was prepared and applied to a thermal cycler (Biometra, Germany). The sequence and thermal profile of each primer are listed in Table 1. The PCR products were analyzed by electrophoresis (Sambrook et al. 1989) and a gel documentation system (Biometra BDA digital, Germany).

3. Results

3.1. Microbiological results

Twenty samples out of 115 feces, stool, and biopsy samples exhibited round, small, and translucent colonies at culture with an incidence of 17.4%. Gram staining showed the presence of Gram-negative, spiral, helical, or curved with blunt ends non-spore-forming microorganisms. The biochemical profile was positive for catalase, positive for oxidase, positive for urea hydrolysis, negative for nitrate reduction, and tolerant to 1.25% NaCl. The distribution of positive culture had a high prevalence in dogs (22.5% (9/40; 6 from feces and 3 from gastric biopsies)). The incidence in cats was 14.3% (5/35; 4 from feces and 1 from fundus biopsy), whereas the rate detected in humans was 15% (6/40; 3 from stool and 3 from fundus biopsy).

3.2. Serological result of *Helicobacter pylori*

Seventy serum samples had a positive antibody reaction using the Asan Easy Test *H. pylori* Ab. The dog serum exhibited a high prevalence (100%) of *H. pylori*, whereas the serum positivity in humans and cats was 83% (25/30) and 50% (15/30), respectively. A total of 58 *H. pylori* Ag were detected in feces and stool samples by Asan Easy Test *H. pylori* Ag. The rates of *H. pylori* Ag were 93% (28/30), 73% (22/30), and 26.6% (8/30) in dog feces, human stool, and cat feces, respectively.

3.3. Prevalence of *Helicobacter* species based on PCR

Fifty out of 115 samples (43.4%) exhibited an amplification band of 398 bp by PCR based on the 16S rRNA primer that was indicative of *Helicobacter* species (Fig. 1).

At the species level, and based on the primers listed in Table 1, *H. heilmannii* was more prevalent (amplification fragments at 580 bp), with a ratio of 16% (8/50). *H. heilmannii* was detected in four dog feces, one dog fundus, one human stool, one human fundus, and one cat fundus samples (Fig. 2).

Three DNA samples yielded a positive amplified fragments at 296 bp corresponding to *H. pylori* based on the *H. pylori* glmM primer, with a prevalence of 6% (3/50); two from human fundus and

Table 1
Primer sequencing, amplified product and cycling conditions of the different primers used in *Helicobacter* species.

Gene	Sequence	Amplified product	Thermal profile							References
			Primary denaturation	Secondary denaturation	Annealing	Extension	Cycles No.	Final extension		
<i>H. felis</i> urea, ureB	GTG AAG CGA CTA AAG ATA AAC AAT GCA CCA AAT CTA ATT CAT AAG AGC	241 bp	94C/ 5 min.	94C/ 30 sec.	62C/ 30 sec.	72C/ 30 sec.	35	72C/ 7 min.	Camargo et al. 2003	
<i>H. heilmannii</i> ureB	GGG CGA TAA AGT GCG CTT G CTG GTC AAT GAG AGC AGG	580 bp			58C/ 40 sec.	72C/ 45 sec.		72C/ 10 min.	Arfaee et al. 2014	
<i>H. pylori</i> glmM	GGA TAA GCT TTT AGG GGT GTT AGG GG GCT TAC TTT CTA ACA CTA ACG CGC	296 bp			57C/ 40 sec.	72C/ 45 sec.		72C/ 10 min.		
<i>Helicobacter</i> spp. 16S rRNA	AAG GAT GAA GCT TCT AGC TTG CTA GTG CTT ATT CGT GAG ATA CCG TCA T	398 bp			50C/ 40 sec.	72C/ 40 sec.		72C/ 10 min.	Tabrizi et al. 2015	




Fig. 1. PCR amplification from dogs, cats and human using 16S rRNA primer. The expected size of the product is 398 bp. Lanes: L, 100–600 bp DNA ladder; Neg, reagent control (no DNA); Pos, DNA extracted from a known positive dog faeces sample; 1–4, DNA extracted from dog faeces and gastric biopsy; ,5,6, DNA extracted from cat faeces and gastric biopsy and 10, 15, 16, DNA extracted from human stool and gastric biopsy.




Fig. 2. PCR amplification using *H. heilmannii* ureB primer. The expected size of the product is 580 bp. Lanes: L, 100–600 bp DNA ladder; Pos, DNA extracted from a known positive dog faeces sample; Neg, reagent control (no DNA); 1–4, DNA extracted from dog faeces and 5, from dog fundus biopsy; 6, DNA extracted from human stool; 7, DNA extracted from fundus biopsy; 8, DNA extracted from cat fundus biopsy.

one from dog fundus biopsies (Fig. 3). All samples were negative for *H. felis*. Different unidentified *Helicobacter* species were detectable with an incidence of 78% (39/50), which warrants further investigation.

4. Discussion

Helicobacter infection is a worldwide zoonotic infection. The incidence of *Helicobacter* infection is very high in Egypt and is attributed mainly to *H. pylori* (Hooi et al. 2017). *Helicobacter* spp. can attack the mucosa of the gastrointestinal tract in humans, wild animals (such as monkeys), and domestic animals (Abdi et al., 2014; Hong et al., 2015). The present investigation detected different *Helicobacter* spp. in companion animals (dogs and cats) in correlation to zoonotic and public health repertoires. We collected 205 samples from apparently healthy companion animals and human patients who suffered from gastrointestinal disturbances and had been in contact with the animals sampled in the Cairo and Giza governorates. All collected samples were similar to those reported previously, including feces, serum, and fundus biopsies from companion animals, as well as human stool and fundus biopsies (Hu et al. 2017).

The diagnostic methods for gastric *Helicobacter* species have been classified as noninvasive or invasive. The noninvasive methods include the detection of bacteria, serologic methods, urea breath test, and bacterial DNA test. The invasive methods include gastric biopsy specimens or brush cytology, histological examination, electron microscopy, urease test, PCR, and *in situ* hybridization (ISH) (Jankowski et al. 2016). The present work revealed a culture prevalence of 17.4% in 115 different samples, with a biochemical profile that was positive for catalase, positive for oxidase, positive for urea hydrolysis, negative for nitrate reduction, and tol-

erant to 1.25% NaCl, which confirmed the non-culturable results of some *Helicobacter* species (Okubo et al. 2017).

Serodetection of *H. pylori* antigens or antibodies is common in human laboratory analyses, and seroconversion does not correlate with the degree of inflammation or colonization density (Shinozaki et al., 2002). Serologic tests for helicobacteriosis in a veterinary setting are not yet clinically available. The detection of fecal *H. pylori* antigens, although possible, has not been adapted for use in veterinary patients. The present study revealed a high detection rate of both *H. pylori* antigens and antibodies in dog feces, followed by human stool and cat feces. The sensitivity and specificity of stool antigen testing for *H. pylori* typically exceed 92%, whereas *H. pylori* IgG serologic testing has a specificity of less than 80% and cross reaction may occur (Crow et al., 2019).

The pathogenesis and therapeutic questions regarding *Helicobacter* species require a simple, sensitive, noninvasive, and readily available specific diagnostic test. PCR analysis would allow *Helicobacter* documentation in dog and cat feces and human stool, as well as in human and animal biopsies (Shinozaki et al., 2002). The authors investigated *Helicobacter* species in dog and cat feces and human stool using PCR of *H. heilmannii ureB*, *H. felis ureB*, and *H. pylori glmM* (against 16S rRNA), with amplification of fragments of 398, 580, 241, and 296 bp, respectively. The rate of detection of *Helicobacter* species was 43.4%. Moreover, *H. heilmannii* was identified in 16% and *H. pylori* was identified in 6% of samples. The detection of *H. heilmannii* in human samples and the presence of *H. pylori* in companion animals (dogs and cats) suggest that those animals act as reservoirs of *Helicobacter* species; some studies have suggested that animals are natural hosts of these species. This implies that *H. pylori* is present in the stomach mucosa with a mild or absent inflammatory response (Hatakeyama, 2014). Moreover, these results support the importance of dogs and cats in the transmission of *Helicobacter* species to humans, especially to the patients who were in contact with the companion animals under investigation. Many authors documented this theory of zoonotic and public health hazard but did not explain the mode of transmission; they only suggested oral or oro-fecal transmission (Shinozaki et al., 2002; Crow et al., 2019).

All samples were *H. felis* negative, and 78% of *Helicobacter* species were unidentified, which warrants further investigation. Gastric *Helicobacter* infections are present in both apparently healthy dogs and dogs presenting with clinical gastric disease, based on many studies (Shinozaki et al., 2002; Saleh et al., 2020).

5. Conclusion

This study confirmed that the serological technique is a screening test, and that PCR is a reliable, sensitive, and diagnostic test for the detection of *Helicobacter* species. Companion animals, including dogs and cats, play a major source as a zoonotic and public health hazard. Finally, dogs and cats act as reservoirs with mild or no clinical signs.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for supporting the work through the research group project No.: (RG-162).




Fig. 3. PCR amplification using *H. pylori* glmM primer. The expected size of the product is 296 bp. Lanes: L, 100–1000 bp DNA ladder; Pos, DNA extracted from a known positive dog feces sample; Neg, reagent control (no DNA); 1, DNA extracted from dog fundus biopsy; 2, 3 DNA extracted from human fundus biopsy.

References

- Abdi, F.S., Jamshidi, S., Moosakhani, F., Sasani, F., 2014. Detection of *Helicobacter* spp. DNA in the colonic biopsies of stray dogs: molecular and histopathological investigation. *Diagn. Pathol.* 9, 50.
- Arfaee, F., Jamshidi, S., Azimirad, M., Dabiri, H., Tabrizi, A.S., Zali, M.R., 2014. PCR-based diagnosis of *Helicobacter* species in the gastric and oral samples of stray dogs. *Comp. Clin. Pathol.* 23, 135–139.
- Bizzozero, G., 1893. Sulleghiaioletubulari del tubogastroenterico e sui rapporti del lorocol Pepitelioidi rivestimentodella mucosa. *Arch. MikrAnat.* 42, 82.
- Bulck, K.V.D., Decostere, A., Baele, M., Driessen, A., Debongnie, J.C., Burette, A., Stolte, M., Ducatelle, R., Haesebrouck, F., 2005. Identification of non-*Helicobacter pylori* spiral organisms in gastric samples from humans, dogs, and Cats. *J. Clin. Microbiol.* 43, 2256–2260.
- Camargo, P.L., Alfieri, A.A., Bracarense, A.P., Menoli, R., Spinosa, S.R., Hagiwara, M.K., 2003. Use of polymerase chain reaction and enzymatic cleavage in the identification of *Helicobacter* spp. in gastric mucosa of human beings from North Paraná, Brazil. *Mem. Inst. Oswaldo Cruz* 98, 265–268.
- Cattoli, G., van Vugt, R., Zanon, R.G., Sanguinetti, V., Chiocchetti, R., Gualtieri, M., Vandenbroucke-Grauls, C.M., Gastra, W., Kusters, J.G., 1999. Occurrence and characterization of gastric *Helicobacter* spp. in naturally infected dogs. *Vet. Microbiol.* 70, 239–250.
- Crow, S.E., Sanguinetti, V., Chiocchetti, R., Gualtieri, M., Vandenbroucke-Grauls, C. M., Gastra, W., Kusters, J.G., 2019. *Helicobacter pylori* Infection. *N. Engl. J. Med.* 380 (12), 1158–1165.
- Forbes, B.A., Sahm, D.F., Weissfeld, A.S., 2007. *Bailey & Scott's Diagnostic Microbiology*. (Mosby-Elsevier 2007).
- Ford, A.C., Moayyedi, P., 2014. Whom should we “test and treat” for *Helicobacter pylori*? *BMJ.* 348, 3320.
- Hatakeyama, M., 2014. *Helicobacter pylori* cagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. *Cell Host Microbe.* 15, 306–316.
- Hong, S., Chung, Y., Kang, W.G., Choi, Y.S., Kim, O., 2015. Comparison of three diagnostic assays for the identification of *Helicobacter* spp. in laboratory dogs. *Lab. Anim. Res.* 31, 86–92.
- Hooi, J.K.Y., Lai, W.Y., Ng, W.K., Suen, M., Underwood, F.E., Tanyingoh, D., Malfertheiner, P., Graham, D.Y., Wong, V., Wu, J., Chan, F., Sung, J., Kaplan, G. G., Ng, S.C., 2017. Global Prevalence of *Helicobacter pylori* infection: systematic review and meta-analysis. *Gastroenterology.* 153, 420–429.
- Hu, Y., Wan, J.H., Li, X.Y., Zhu, Y., Graham, D.Y., Lu, N.H., 2017. Systematic review with metaanalysis: the global recurrence rate of *Helicobacter pylori*. *Aliment Pharmacol. Ther.* 46, 773–779.
- Jankowski, M., Spuzak, J., Kubiak, K., Glińska-Suchocka, K., Biernat, M., 2016. Detection of gastric *Helicobacter* spp. in stool samples of dogs with gastritis. *Pol. J. Vet. Sci.* 19, 237–243.
- Ladeira, M.S.P., Salvadori, D.M.F., Rodrigues, A.M., *Biopatologia do*, 2003. *Helicobacter pylori*. *J. Bras. Patol. Med. Lab.* 39, 335–342.
- Lockard, V.G., Boler, R.K., 1970. Ultrastructure of a spiraled microorganism in the gastric mucosa of dogs. *Am. J. Vet. Res.* 31, 1453–1461.
- Morgner, A., Lehn, N., Andersen, L.P., Thiede, C., Bennedsen, M., Trebesius, K., Neubauer, B., Neubauer, A., Stlitz, M., Bayerdörfer, E., 2000. *Helicobacter heilmannii*- associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. *Gastroenterology* 118, 821–828.
- Okubo, B.M., Ricci-Azevedo, R., Zobiolo, N.N., Buccini, D.F., Moreno, S.E., 2017. Prevalence of *Helicobacter* spp. in dogs from Campo Grande-MS. *Cienc. Anim. Bras Goiânia* 18, 1–10.
- Owen, R.J., 1998. *Helicobacter*-species classification and identification. *Br. Med. Bull.* 54, 17–30.
- Rappin, J., 1958. Contribution à l'étude des bactéries de la bouche à l'état normal et dans la fièvre typhoïde. Ph.D Thesis, Collège de France, Nantes, 1881. *Ref. Am. J. Vet. Res.* 19, 677–680.
- Saleh, G.S.Z., El-Enbaawy, M.I.H., Abd El-Rahman, S.S., Marouf, S., 2020. Increased production of matrix metalloproteinases in *Helicobacter pylori* infection that stimulates gastric cancer stem cells. *Int. J. Vet. Sci.* 9, 355–360.
- Salomon, H., 1896. Ueber das Spirillum des Säugetiermagens und sein Verhalten zu den Belegzellen. *Zentralbl. Bakteriol. Parasitenkd. Infektionskrankh.* 1. Abt. 19, 433–442.
- Sambrook, J., Fritsch, E.F., Maniatis, 1989. *Molecular cloning. A laboratory manual*. Vol.1. Cold Spring Harbor Laboratory Press, New York.
- Shinozaki, J.K., Sellon, R.K., Cantor, G.H., Besser, T.E., Mealey, K.L., Vaden, S.L., 2002. Fecal polymerase chain reaction with 16S ribosomal RNA primers can detect the presence of gastrointestinal *Helicobacter* in dogs. *J. Vet. Intern. Med.* 16, 426–432.
- Tabrizi, A.S., Derakhshandeh, A., Esfandiari, A., Atashi, Z.A., 2015. Identification of *Helicobacter* spp. in gastrointestinal tract, pancreas and hepatobiliary system of stray cats. *Iran J. Vet. Res.* 16, 374–376.